SCHEMBL16620820

SCHEMBL16620820

[CH2]CCOc1ccc2cc(Br)ccc2n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 1/20 0.46
MEN1 O00255 1/20 0.38
MAPT P10636 1/20 0.38
KMT2A Q03164 1/20 0.38
HTT P42858 3/20 0.36
ALDH1A1 P00352 2/20 0.36
LMNA P02545 2/20 0.36
HPGD P15428 2/20 0.36
KDM4E B2RXH2 1/20 0.36
MTOR P42345 1/20 0.36
NCOA1 Q15788 1/20 0.36
NCOA3 Q9Y6Q9 1/20 0.36
TLR2 O60603 1/20 0.36
CYP1A2 P05177 1/20 0.35
CYP2C19 P33261 1/20 0.35
THRB P10828 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
SCN7A Q01118 1/20 0.34
HDAC1 Q13547 2/20 0.34
HDAC2 Q92769 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22117590 0.84 BACE1 (0.46) BACE1MEN1MAPTKMT2AHTT
SCHEMBL22117596 0.84 BACE1 (0.46) BACE1MEN1MAPTKMT2AHTT
SCHEMBL29455719 0.84 BACE1 (0.46) BACE1MEN1MAPTKMT2AHTT
SCHEMBL13196924 0.84 BACE1 (0.46) BACE1MEN1MAPTKMT2AHTT
SCHEMBL29455889 0.83 BACE1 (0.45) BACE1MEN1MAPTKMT2AHTT
SCHEMBL16621225 0.83 BACE1 (0.45) BACE1MEN1MAPTKMT2AALDH1A1
SCHEMBL17511357 0.81 TLR8 (0.47) BACE1MAPTHTTLMNAHPGD
SCHEMBL2440427 0.80 MAPT (0.48) BACE1MAPTHTTLMNAHPGD
SCHEMBL18109808 0.80 HTR7 (0.47) BACE1MAPTKMT2AALDH1A1LMNA
SCHEMBL2802333 0.79 CYP1B1 (0.44) BACE1MEN1MAPTKMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11787786-B2 Fused 1,4-dihydrodioxin derivatives as inhibitors of heat shock transcription factor 1 CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2023-10-17 US disclosed
US-20220220097-A1 FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1 CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2022-07-14 US disclosed
EP-3521286-B1 FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1 CANCER RESEARCH TECH LTD (GB) 2021-09-29 EP disclosed
US-11124501-B2 Fused 1,4-dihydrodioxin derivatives as inhibitors of heat shock transcription factor I CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2021-09-21 US disclosed
EP-3521286-A1 FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1 Cancer Research Technology Ltd. (GB) 2019-08-07 EP disclosed
US-20190106413-A1 INHIBITOR COMPOUNDS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2019-04-11 US disclosed
EP-3052492-B1 FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1 CANCER RESEARCH TECH LTD (GB) 2019-03-27 EP disclosed
US-9701664-B2 Fused 1,4-dihydrodioxin derivatives as inhibitors of heat shock transcription factor 1 CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2017-07-11 US disclosed
US-20160289216-A1 FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1 CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2016-10-06 US disclosed
EP-3052492-A1 FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1 Cancer Research Technology Limited (GB) 2016-08-10 EP disclosed
WO-2015049535-A1 FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1 CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2015-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190106413-A1 INHIBITOR COMPOUNDS HSF1, HSP90AB1, HSP90AA1 BACE1 1693/4885MEN1 1974/4885MAPT 1193/4885
US-20160289216-A1 FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1 HSF1, HSP90AB1, HSPB1 BACE1 2355/4885MEN1 3540/4885MAPT 2590/4885
US-11787786-B2 Fused 1,4-dihydrodioxin derivatives as inhibitors of heat shock transcription factor 1 HSF1, HSP90AB1, HSPB1 BACE1 2289/4885MEN1 2854/4885MAPT 2888/4885
US-20220220097-A1 FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1 HSF1, HSP90AB1, HSPB1 BACE1 2289/4885MEN1 2854/4885MAPT 2888/4885
US-11124501-B2 Fused 1,4-dihydrodioxin derivatives as inhibitors of heat shock transcription factor I HSF1, HSP90AB1, HSPB1 BACE1 2449/4885MEN1 3522/4885MAPT 2665/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.